Tecentriq assumes pole position with FDA approval but Keytruda looms in triple negative breast cancer, says GlobalData
On March 8, the FDA granted the accelerated approval of Roche’s programmed cell death protein 1 (PD-1) inhibitor Tecentriq in combination with Abraxane (protein-bound paclitaxel) for the treatment of locally advanced or metastatic triple-negative breast cancer (TNBC).
Adam Pearson, PhD, Oncology and Hematology Analyst at GlobalData, a leading data and analytics company, offers his view on the FDA approval of Tecentriq for TNBC:
“The emergence of Tecentriq as the first-in-class PD-1 inhibitor in breast cancer marks the first approval of an immuno-oncology drug in breast cancer and signifies the introduction of a new treatment strategy in a therapeutically elusive subset of breast cancer. It represents a win for Roche in a PD-1 inhibitor market dominated by Merck & Co.’s Keytruda and Bristol-Myers Squibb’s (BMS) Opdivo. Tecentriq is poised to temporarily monopolize the TNBC market until Merck & Co. is expected to release its Keytruda data from two Phase III trials this year.
“Therefore, despite the first-in-class success for Tecentriq in TNBC, Merck & Co.’s active testing of Keytruda in a single-agent setting and in combination with chemotherapy of physician’s choice, may ultimately allow Keytruda to be used in broader patient populations.
“Further opportunities exist in the neoadjuvant/adjuvant setting, in hormone-receptor-positive, and HER-2-positive breast cancers and finally, through novel combinations of PD-1 inhibitors with the approved poly ADP ribose polymerase (PARP) inhibitors in breast cancer patients harboring BRCA1 (breast cancer type 1 susceptibility protein) mutations. Each is an active area of investigation.
“Needless to say, competition will be fierce and each of the immuno-oncology players will strive to carve out a therapeutic niche within the breast cancer market.”
For more information
To gain access to our latest press releases: GlobalData Media Centre
Analysts available for comment. Please contact the GlobalData Press Office:
EMEA & Americas: +44 (0)207 832 4399
Asia-Pacific: +91 40 6616 6809
For expert analysis on developments in your industry, please connect with us on:
GlobalData | LinkedIn | Twitter
4,000 of the world’s largest companies, including over 70% of FTSE 100 and 60% of Fortune 100 companies, make more timely and better business decisions thanks to GlobalData’s unique data, expert analysis and innovative solutions, all in one platform. GlobalData’s mission is to help our clients decode the future to be more successful and innovative across a range of industries, including the healthcare, consumer, retail, financial, technology and professional services sectors.